A prior written permission of the approver(Depositor) is necessary for any kind of use including academic use and for-profit use.
Remarks
approver's address
×
English
Address
Niigata university Graduate School of Medical and Dental Sciences 757, 1-bancho, asahimachidori, cyuo-ku, niigata-city, Niigata Japan
Dr.KAWASHIMA Hiroyuki
Fax. +81-25-227-0782
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
22145
Chow T, Humble W, Lucarelli E, Onofrillo C, Choong PF, Di Bella C, Duchi S.
Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management.iScience
2024
27(9):110251
PubMed ID: 39286504
DOI: 10.1016/j.isci.2024.110251
17096
Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M, Kobayashi A, Lebel M, Kawaguchi T, Sugawara M, Tsuji-Takayama K, Ichihara K, Funauchi Y, Ae K, Matsumoto S, Sugiura Y, Takeuchi K, Noda T, Katayama R, Fujita N.
Targeting Podoplanin for the Treatment of OsteosarcomaClin Cancer Res
2022
28(12):2633-2645
PubMed ID: 35381070
DOI: 10.1158/1078-0432.CCR-21-4509
13409
Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, Asano N, Nakamura M, Matsumoto M, Nakayama R, Kondo T, Kawai A, Kobayashi E, Yamada T.
Direct conversion of osteosarcoma to adipocytes by targeting TNIK.JCI Insight
2021
PubMed ID: 33400690
DOI: 10.1172/jci.insight.137245
15919
Takagi S, Sasaki Y, Koike S, Takemoto A, Seto Y, Haraguchi M, Ukaji T, Kawaguchi T, Sugawara M, Saito M, Funauchi Y, Ae K, Matsumoto S, Fujita N, Katayama R.
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasisOncogene
2021
40(36):5548-5558
PubMed ID: 34302117
DOI: 10.1038/s41388-021-01956-6
10919Antitumor activities of BIBF 1120, BI 860585, and BI 836845 in preclinical models of sarcomaIntegr Mol Med
2016
3: 755-760
DOI: 10.15761/IMM.1000239
6428
Arai K, Sakamoto R, Kubota D, Kondo T.
Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system.Proteomics
2013
13(15):2351-60
PubMed ID: 23712969
DOI: 10.1002/pmic.201300053